The DOI matches its Crossref record; 188 of the 188 references it cites were found in a registry or an index.
Targeting PI3K/AKT signaling for treatment of idiopathic pulmonary fibrosis
Open accessAbstract
Idiopathic pulmonary fibrosis (IPF) is a chronic progressive fibrotic interstitial pneumonia with unknown causes. The incidence rate increases year by year and the prognosis is poor without cure. Recently, phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/AKT) signaling pathway can be considered as a master regulator for IPF. The contribution of the PI3K/AKT in fibrotic processes is increasingly prominent, with PI3K/AKT inhibitors currently under clinical evaluation in IPF. Therefore, PI3K/AKT represents a critical signaling node during fibrogenesis with potential implications for the development of novel anti-fibrotic strategies. This review epitomizes the progress that is being made in understanding the complex interpretation of the cause of IPF, and demonstrates that PI3K/AKT can directly participate to the greatest extent in the formation of IPF or cooperate with other pathways to promote the development of fibrosis. We further summarize promising PI3K/AKT inhibitors with IPF treatment benefits, including inhibitors in clinical trials and pre-clinical studies and natural products, and discuss how these inhibitors mitigate fibrotic progression to explore possible potential agents, which will help to develop effective treatment strategies for IPF in the near future.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular mechanisms of epithelial–mesenchymal transition
Lamouille, S., Xu, J., & Derynck, R. (2014) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm3758 · Cited by 8,091
Protective and pathogenic functions of macrophage subsets
Murray, P. J., & Wynn, T. A. (2011) · Nature Reviews Immunology · doi:10.1038/nri3073 · Cited by 5,269
Meijer, L., Nelson, D. J., Riazanski, V., Gabdoulkhakova, A. G., Hery-Arnaud, G., Le Berre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., et al. (2016) · Journal of Innate Immunity · doi:10.1159/000444256 · Cited by 4,992
The evolution of phosphatidylinositol 3-kinases as regulators of growth and metabolism
Engelman, J. A., Luo, J., & Cantley, L. C. (2006) · Nature Reviews Genetics · doi:10.1038/nrg1879 · Cited by 3,330
Transforming Growth Factor β in Tissue Fibrosis
Epstein, F. H., Border, W. A., & Noble, N. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199411103311907 · Cited by 3,069
TGF-β signaling and the fibrotic response
Leask, A., & Abraham, D. J. (2004) · The FASEB Journal · doi:10.1096/fj.03-1273rev · Cited by 2,319
Extracellular Matrix Degradation and Remodeling in Development and Disease
Lu, P., Takai, K., Weaver, V. M., & Werb, Z. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a005058 · Cited by 2,265
King, T. E., Pardo, A., & Selman, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60052-4 · Cited by 2,194
Richeldi, L., Collard, H. R., & Jones, M. G. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30866-8 · Cited by 2,020
Selman, M., King, T. E., & Pardo, A. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00015 · Cited by 1,786
Fibrotic disease and the TH1/TH2 paradigm
Wynn, T. A. (2004) · Nature Reviews Immunology · doi:10.1038/nri1412 · Cited by 1,765
Cellular senescence mediates fibrotic pulmonary disease
Schafer, M. J., White, T. A., Iijima, K., Haak, A. J., Ligresti, G., Atkinson, E. J., Oberg, A. L., Birch, J., Salmonowicz, H., Zhu, Y., et al. (2017) · Nature Communications · doi:10.1038/ncomms14532 · Cited by 1,613
Targeting PI3K in cancer: mechanisms and advances in clinical trials
Yang, J., Nie, J., Ma, X., Wei, Y., Peng, Y., & Wei, X. (2019) · Molecular Cancer · doi:10.1186/s12943-019-0954-x · Cited by 1,520
Integrating mechanisms of pulmonary fibrosis
Wynn, T. A. (2011) · Journal of Experimental Medicine · doi:10.1084/jem.20110551 · Cited by 1,274
Sime, P. J., Xing, Z., Graham, F. L., Csaky, K. G., & Gauldie, J. (1997) · Journal of Clinical Investigation · doi:10.1172/jci119590 · Cited by 1,050
Global incidence and mortality of idiopathic pulmonary fibrosis: a systematic review
Hutchinson, J., Fogarty, A., Hubbard, R., & McKeever, T. (2015) · European Respiratory Journal · doi:10.1183/09031936.00185114 · Cited by 913
Perspective Article: Tissue repair, contraction, and the myofibroblast
Desmoulière, A., Chaponnier, C., & Gabbiani, G. (2005) · Wound Repair and Regeneration · doi:10.1111/j.1067-1927.2005.130102.x · Cited by 892
Narasaraju, T., Yang, E., Samy, R. P., Ng, H. H., Poh, W. P., Liew, A.-A., Phoon, M. C., van Rooijen, N., & Chow, V. T. (2011) · The American Journal of Pathology · doi:10.1016/j.ajpath.2011.03.013 · Cited by 890
Akt in cancer: Mediator and more
Revathidevi, S., & Munirajan, A. K. (2019) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.002 · Cited by 691
Huang, S. C.-C., Smith, A. M., Everts, B., Colonna, M., Pearce, E. L., Schilling, J. D., & Pearce, E. J. (2016) · Immunity · doi:10.1016/j.immuni.2016.09.016 · Cited by 667
Neutrophils: Between Host Defence, Immune Modulation, and Tissue Injury
Kruger, P., Saffarzadeh, M., Weber, A. N. R., Rieber, N., Radsak, M., von Bernuth, H., Benarafa, C., Roos, D., Skokowa, J., & Hartl, D. (2015) · PLOS Pathogens · doi:10.1371/journal.ppat.1004651 · Cited by 657
Zuo, F., Kaminski, N., Eugui, E., Allard, J., Yakhini, Z., Ben-Dor, A., Lollini, L., Morris, D., Kim, Y., DeLustro, B., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.092134099 · Cited by 620
Effects of cigarette smoke on the human airway epithelial cell transcriptome
Spira, A., Beane, J., Shah, V., Liu, G., Schembri, F., Yang, X., Palma, J., & Brody, J. S. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401422101 · Cited by 619
A new role for the PI3K/Akt signaling pathway in the epithelial-mesenchymal transition
Xu, W., Yang, Z., & Lu, N. (2015) · Cell Adhesion & Migration · doi:10.1080/19336918.2015.1016686 · Cited by 608
Safety Aspects of the Use of Quercetin as a Dietary Supplement
Andres, S., Pevny, S., Ziegenhagen, R., Bakhiya, N., Schäfer, B., Hirsch‐Ernst, K. I., & Lampen, A. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700447 · Cited by 588
PI 3-kinase p110β: a new target for antithrombotic therapy
Jackson, S. P., Schoenwaelder, S. M., Goncalves, I., Nesbitt, W. S., Yap, C. L., Wright, C. E., Kenche, V., Anderson, K. E., Dopheide, S. M., Yuan, Y., et al. (2005) · Nature Medicine · doi:10.1038/nm1232 · Cited by 580
Lipson, K. E., Wong, C., Teng, Y., & Spong, S. (2012) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-5-s1-s24 · Cited by 575
Idiopathic pulmonary fibrosis: pathogenesis and management
Sgalla, G., Iovene, B., Calvello, M., Ori, M., Varone, F., & Richeldi, L. (2018) · Respiratory Research · doi:10.1186/s12931-018-0730-2 · Cited by 573
Königshoff, M., Kramer, M., Balsara, N., Wilhelm, J., Amarie, O. V., Jahn, A., Rose, F., Fink, L., Seeger, W., Schaefer, L., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci33950 · Cited by 558
Cellular Senescence as a Mechanism and Target in Chronic Lung Diseases
Barnes, P. J., Baker, J., & Donnelly, L. E. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1975tr · Cited by 555
Molecular Targets in Pulmonary Fibrosis
Scotton, C. J., & Chambers, R. C. (2007) · Chest · doi:10.1378/chest.06-2568 · Cited by 538
Up-Regulation and Profibrotic Role of Osteopontin in Human Idiopathic Pulmonary Fibrosis
Pardo, A., Gibson, K., Cisneros, J., Richards, T. J., Yang, Y., Becerril, C., Yousem, S., Herrera, I., Ruiz, V., Selman, M., et al. (2005) · PLoS Medicine · doi:10.1371/journal.pmed.0020251 · Cited by 489
Inhibition of the PI3K/AKT/mTOR Pathway in Solid Tumors
LoRusso, P. M. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.0018 · Cited by 470
Kuhn, C., Boldt, J., King, T. E., Crouch, E., Vartio, T., & McDonald, J. A. (1989) · American Review of Respiratory Disease · doi:10.1164/ajrccm/140.6.1693 · Cited by 466
ER stress negatively regulates AKT/TSC/mTOR pathway to enhance autophagy
Qin, L., Wang, Z., Tao, L., & Wang, Y. (2010) · Autophagy · doi:10.4161/auto.6.2.11062 · Cited by 435
Lawson, W. E., Crossno, P. F., Polosukhin, V. V., Roldan, J., Cheng, D.-S., Lane, K. B., Blackwell, T. R., Xu, C., Markin, C., Ware, L. B., et al. (2008) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00382.2007 · Cited by 429
Macrophage Akt1 Kinase-Mediated Mitophagy Modulates Apoptosis Resistance and Pulmonary Fibrosis
Larson-Casey, J. L., Deshane, J. S., Ryan, A. J., Thannickal, V. J., & Carter, A. B. (2016) · Immunity · doi:10.1016/j.immuni.2016.01.001 · Cited by 428
Meltzer, E. B., & Noble, P. W. (2008) · Orphanet Journal of Rare Diseases · doi:10.1186/1750-1172-3-8 · Cited by 407
Lehmann, M., Korfei, M., Mutze, K., Klee, S., Skronska-Wasek, W., Alsafadi, H. N., Ota, C., Costa, R., Schiller, H. B., Lindner, M., et al. (2017) · European Respiratory Journal · doi:10.1183/13993003.02367-2016 · Cited by 403
Giri, S. N., Hyde, D. M., & Hollinger, M. A. (1993) · Thorax · doi:10.1136/thx.48.10.959 · Cited by 402
M1 and M2 Macrophages: The Chicken and the Egg of Immunity
Mills, C. D., & Ley, K. (2014) · Journal of Innate Immunity · doi:10.1159/000364945 · Cited by 401
Platelet-derived growth factor in idiopathic pulmonary fibrosis.
Antoniades, H. N., Bravo, M. A., Avila, R. E., Galanopoulos, T., Neville-Golden, J., Maxwell, M., & Selman, M. (1990) · Journal of Clinical Investigation · doi:10.1172/jci114808 · Cited by 384
Discovery of GSK2126458, a Highly Potent Inhibitor of PI3K and the Mammalian Target of Rapamycin
Knight, S. D., Adams, N. D., Burgess, J. L., Chaudhari, A. M., Darcy, M. G., Donatelli, C. A., Luengo, J. I., Newlander, K. A., Parrish, C. A., Ridgers, L. H., et al. (2010) · ACS Medicinal Chemistry Letters · doi:10.1021/ml900028r · Cited by 373
Sapey, E., Greenwood, H., Walton, G., Mann, E., Love, A., Aaronson, N., Insall, R. H., Stockley, R. A., & Lord, J. M. (2014) · Blood · doi:10.1182/blood-2013-08-519520 · Cited by 358
Idiopathic pulmonary fibrosis: multiple causes and multiple mechanisms?
Maher, T. M., Wells, A. U., & Laurent, G. J. (2007) · European Respiratory Journal · doi:10.1183/09031936.00069307 · Cited by 341
Research review on the pharmacological effects of astragaloside IV
Li, L., Hou, X., Xu, R., Liu, C., & Tu, M. (2017) · Fundamental & Clinical Pharmacology · doi:10.1111/fcp.12232 · Cited by 330
Genome-wide association study of susceptibility to idiopathic pulmonary fibrosis
Allen, R. J., Guillen-Guio, B., Oldham, J. M., Ma, S.-F., Dressen, A., Paynton, M. L., Kraven, L. M., Obeidat, M., Li, X., Ng, M., et al. (2020) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201905-1017oc · Cited by 329
Khalil, N., O'Connor, R. N., Flanders, K. C., & Unruh, H. (1996) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.14.2.8630262 · Cited by 328
Pechkovsky, D. V., Prasse, A., Kollert, F., Engel, K. M. Y., Dentler, J., Luttmann, W., Friedrich, K., Müller-Quernheim, J., & Zissel, G. (2010) · Clinical Immunology · doi:10.1016/j.clim.2010.06.017 · Cited by 328
Minagawa, S., Araya, J., Numata, T., Nojiri, S., Hara, H., Yumino, Y., Kawaishi, M., Odaka, M., Morikawa, T., Nishimura, S. L., et al. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00097.2010 · Cited by 323
Idiopathic pulmonary fibrosis: Epithelial-mesenchymal interactions and emerging therapeutic targets
Hewlett, J. C., Kropski, J. A., & Blackwell, T. S. (2018) · Matrix Biology · doi:10.1016/j.matbio.2018.03.021 · Cited by 321
Pirfenidone: Molecular mechanisms and potential clinical applications in lung disease
Ruwanpura, S. M., Thomas, B. J., & Bardin, P. G. (2020) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2019-0328tr · Cited by 317
The Role of Immune and Inflammatory Cells in Idiopathic Pulmonary Fibrosis
Desai, O., Winkler, J., Minasyan, M., & Herzog, E. L. (2018) · Frontiers in Medicine · doi:10.3389/fmed.2018.00043 · Cited by 314
Ihle, N. T., Williams, R., Chow, S., Chew, W., Berggren, M. I., Paine-Murrieta, G., Minion, D. J., Halter, R. J., Wipf, P., Abraham, R., et al. (2004) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.763.3.7 · Cited by 313
RAS and RHO Families of GTPases Directly Regulate Distinct Phosphoinositide 3-Kinase Isoforms
Fritsch, R., de Krijger, I., Fritsch, K., George, R., Reason, B., Kumar, M. S., Diefenbacher, M., Stamp, G., & Downward, J. (2013) · Cell · doi:10.1016/j.cell.2013.04.031 · Cited by 306
Barron, L., & Wynn, T. A. (2011) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00414.2010 · Cited by 304
Papa, A., & Pandolfi, P. P. (2019) · Biomolecules · doi:10.3390/biom9040153 · Cited by 303
Alveolar epithelial cell death adjacent to underlying myofibroblasts in advanced fibrotic human lung
Uhal, B. D., Joshi, I., Hughes, W. F., Ramos, C., Pardo, A., & Selman, M. (1998) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.1998.275.6.l1192 · Cited by 296
Cooperative interaction of CTGF and TGF-β in animal models of fibrotic disease
Wang, Q., Usinger, W., Nichols, B., Gray, J., Xu, L., Seeley, T. W., Brenner, M., Guo, G., Zhang, W., Oliver, N., et al. (2011) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-4-4 · Cited by 278
Wu, L., Zhang, Q., Mo, W., Feng, J., Li, S., Li, J., Liu, T., Xu, S., Wang, W., Lu, X., et al. (2017) · Scientific Reports · doi:10.1038/s41598-017-09673-5 · Cited by 271
Activating Wnt/β-catenin signaling pathway for disease therapy: Challenges and opportunities
Huang, P., Yan, R., Zhang, X., Wang, L., Ke, X., & Qu, Y. (2019) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.11.008 · Cited by 268
Galli, J. A., Pandya, A., Vega‐Olivo, M., Dass, C., Zhao, H., & Criner, G. J. (2017) · Respirology · doi:10.1111/resp.13024 · Cited by 257
Sun, L., Louie, M. C., Vannella, K. M., Wilke, C. A., LeVine, A. M., Moore, B. B., & Shanley, T. P. (2011) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00122.2010 · Cited by 251
Telomerase and idiopathic pulmonary fibrosis
Armanios, M. (2012) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2011.10.013 · Cited by 245
Hu, X., Xu, Q., Wan, H., Hu, Y., Xing, S., Yang, H., Gao, Y., & He, Z. (2020) · Laboratory Investigation · doi:10.1038/s41374-020-0404-9 · Cited by 244
γδ T cells protect against lung fibrosis via IL-22
Simonian, P. L., Wehrmann, F., Roark, C. L., Born, W. K., O'Brien, R. L., & Fontenot, A. P. (2010) · Journal of Experimental Medicine · doi:10.1084/jem.20100061 · Cited by 242
Horowitz, J. C., Rogers, D. S., Sharma, V., Vittal, R., White, E. S., Cui, Z., & Thannickal, V. J. (2007) · Cellular Signalling · doi:10.1016/j.cellsig.2006.10.001 · Cited by 242
Evans, C. M., Fingerlin, T. E., Schwarz, M. I., Lynch, D., Kurche, J., Warg, L., Yang, I. V., & Schwartz, D. A. (2016) · Physiological Reviews · doi:10.1152/physrev.00004.2016 · Cited by 238
Transforming Growth Factor-β: Master Regulator of the Respiratory System in Health and Disease
Aschner, Y., & Downey, G. P. (2016) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2015-0391tr · Cited by 237
The leading role of epithelial cells in the pathogenesis of idiopathic pulmonary fibrosis
Selman, M., & Pardo, A. (2020) · Cellular Signalling · doi:10.1016/j.cellsig.2019.109482 · Cited by 225
Neutrophil elastase promotes myofibroblast differentiation in lung fibrosis
Gregory, A. D., Kliment, C. R., Metz, H. E., Kim, K.-H., Kargl, J., Agostini, B. A., Crum, L. T., Oczypok, E. A., Oury, T. A., & Houghton, A. M. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi1014-493r · Cited by 216
Pan, L.-H., Yamauchi, K., Uzuki, M., Nakanishi, T., Takigawa, M., Inoue, H., & Sawai, T. (2001) · European Respiratory Journal · doi:10.1183/09031936.01.00074101 · Cited by 207
FAK Structure and Regulation by Membrane Interactions and Force in Focal Adhesions
Tapial Martínez, P., López Navajas, P., & Lietha, D. (2020) · Biomolecules · doi:10.3390/biom10020179 · Cited by 206
Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF
Mercer, P. F., Woodcock, H. V., Eley, J. D., Platé, M., Sulikowski, M. G., Durrenberger, P. F., Franklin, L., Nanthakumar, C. B., Man, Y., Genovese, F., et al. (2016) · Thorax · doi:10.1136/thoraxjnl-2015-207429 · Cited by 206
Hsu, H.-S., Liu, C.-C., Lin, J.-H., Hsu, T.-W., Hsu, J.-W., Su, K., & Hung, S.-C. (2017) · Scientific Reports · doi:10.1038/s41598-017-14612-5 · Cited by 205
Hohmann, M. S., Habiel, D. M., Coelho, A. L., Verri, W. A., & Hogaboam, C. M. (2019) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2017-0289oc · Cited by 202
Mechanisms of Alveolar Epithelial Injury, Repair, and Fibrosis
Chambers, R. C., & Mercer, P. F. (2015) · Annals of the American Thoracic Society · doi:10.1513/annalsats.201410-448mg · Cited by 202
Hou, J., Shi, J., Chen, L., Lv, Z., Chen, X., Cao, H., Xiang, Z., & Han, X. (2018) · Cell Communication and Signaling · doi:10.1186/s12964-018-0300-8 · Cited by 202
Extracellular matrix in normal and fibrotic human lungs.
Raghu, G., Striker, L. J., Hudson, L. D., & Striker, G. E. (1985) · PubMed · doi:10.1164/arrd.1985.131.2.281 · Cited by 201
Manzenreiter, R., Kienberger, F., Marcos, V., Schilcher, K., Krautgartner, W. D., Obermayer, A., Huml, M., Stoiber, W., Hector, A., Griese, M., et al. (2012) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2011.09.008 · Cited by 199
C-X-C Motif Chemokine 13 (CXCL13) Is a Prognostic Biomarker of Idiopathic Pulmonary Fibrosis
Vuga, L. J., Tedrow, J. R., Pandit, K. V., Tan, J., Kass, D. J., Xue, J., Chandra, D., Leader, J. K., Gibson, K. F., Kaminski, N., et al. (2014) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201309-1592oc · Cited by 197
Zhai, C., Cheng, J., Mujahid, H., Wang, H., Kong, J., Yin, Y., Li, J., Zhang, Y., Ji, X., & Chen, W. (2014) · PLoS ONE · doi:10.1371/journal.pone.0090563 · Cited by 194
Th17-Polarized Immune Response in a Murine Model of Hypersensitivity Pneumonitis and Lung Fibrosis
Simonian, P. L., Roark, C. L., Wehrmann, F., Lanham, A. K., Diaz del Valle, F., Born, W. K., O’Brien, R. L., & Fontenot, A. P. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.182.1.657 · Cited by 190
Kotani, I., Sato, A., Hayakawa, H., Urano, T., Takada, Y., & Takada, A. (1995) · Thrombosis Research · doi:10.1016/0049-3848(95)00025-9 · Cited by 188
Chaqour, B., & Goppelt‐Struebe, M. (2006) · The FEBS Journal · doi:10.1111/j.1742-4658.2006.05360.x · Cited by 187
VEGF and FGF-2: Promising targets for the treatment of respiratory disorders
Laddha, A. P., & Kulkarni, Y. A. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2019.08.003 · Cited by 187
The Role of the Mammalian Target of Rapamycin (mTOR) in Pulmonary Fibrosis
Lawrence, J., & Nho, R. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19030778 · Cited by 183
Molecular Mechanisms of Pulmonary Fibrogenesis and Its Progression to Lung Cancer: A Review
Kinoshita, T., & Goto, T. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061461 · Cited by 176
Common Pathogenic Mechanisms Between Idiopathic Pulmonary Fibrosis and Lung Cancer
Tzouvelekis, A., Gomatou, G., Bouros, E., Trigidou, R., Tzilas, V., & Bouros, D. (2019) · Chest · doi:10.1016/j.chest.2019.04.114 · Cited by 176
Baker, J. R., Vuppusetty, C., Colley, T., Papaioannou, A. I., Fenwick, P., Donnelly, L., Ito, K., & Barnes, P. J. (2016) · Scientific Reports · doi:10.1038/srep35871 · Cited by 175
Esposito, D. B., Lanes, S., Donneyong, M. M., Holick, C. N., Lasky, J. A., Lederer, D. J., Nathan, S. D., O’Quinn, S., Parker, J. M., & Tran, T. N. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201504-0818oc · Cited by 174
The emerging role of PI3K/AKT-mediated epigenetic regulation in cancer
Spangle, J. M., Roberts, T. M., & Zhao, J. J. (2017) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2017.03.002 · Cited by 172
Qian, W., Cai, X., Qian, Q., Zhang, W., & Wang, D. (2018) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.13725 · Cited by 172
Self-citationThe role of infection in the pathogenesis of idiopathic pulmonary fibrosis
Molyneaux, P. L., & Maher, T. M. (2013) · European Respiratory Review · doi:10.1183/09059180.00000713 · Cited by 171
Strategies for anti-fibrotic therapies
Rosenbloom, J., Mendoza, F. A., & Jimenez, S. A. (2013) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2012.12.007 · Cited by 170
New developments in fibroblast and myofibroblast biology: Implications for fibrosis and scleroderma
Abraham, D. J., Eckes, B., Rajkumar, V., & Krieg, T. (2007) · Current Rheumatology Reports · doi:10.1007/s11926-007-0008-z · Cited by 166
Metalloproteinases in idiopathic pulmonary fibrosis
Dancer, R. C. A., Wood, A. M., & THICKETT, D. R. (2011) · European Respiratory Journal · doi:10.1183/09031936.00024711 · Cited by 164
Involvement of Endoplasmic Reticulum Stress in Myofibroblastic Differentiation of Lung Fibroblasts
Baek, H. A., Kim, D. S., Park, H. S., Jang, K. Y., Kang, M. J., Lee, D. G., Moon, W. S., Chae, H. J., & Chung, M. J. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0121oc · Cited by 163
Conte, E., Fruciano, M., Fagone, E., Gili, E., Caraci, F., Iemmolo, M., Crimi, N., & Vancheri, C. (2011) · PLoS ONE · doi:10.1371/journal.pone.0024663 · Cited by 162
Plasma B Lymphocyte Stimulator and B Cell Differentiation in Idiopathic Pulmonary Fibrosis Patients
Xue, J., Kass, D. J., Bon, J., Vuga, L., Tan, J., Csizmadia, E., Otterbein, L., Soejima, M., Levesque, M. C., Gibson, K. F., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203476 · Cited by 161
Traditional Chinese medicine for pulmonary fibrosis therapy: Progress and future prospects
Li, L., & Kan, L. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.12.042 · Cited by 160
Idiopathic Pulmonary Fibrosis: Current Status, Recent Progress, and Emerging Targets
Liu, Y.-M., Nepali, K., & Liou, J. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00935 · Cited by 154
A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis
Lukey, P. T., Harrison, S. A., Yang, S., Man, Y., Holman, B. F., Rashidnasab, A., Azzopardi, G., Grayer, M., Simpson, J. K., Bareille, P. J., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01992-2018 · Cited by 154
Pathologic Caveolin-1 Regulation of PTEN in Idiopathic Pulmonary Fibrosis
Hong, X., Khalil, W., Kahm, J., Jessurun, J., Kleidon, J., & Henke, C. A. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.091117 · Cited by 152
Roberts, P. J., Usary, J., Darr, D. B., Dillon, P. M., Pfefferle, A. D., Whittle, M. C., Duncan, J. S., Johnson, S. M., Combest, A. J., Jin, J. J., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0563 · Cited by 148
Hill, C. N., Jones, M. G., Davies, D. E., & Wang, Y. (2019) · Journal of Lung Health and Diseases · doi:10.29245/2689-999x/2019/2.1149 · Cited by 147
A neutrophil elastase inhibitor prevents bleomycin-induced pulmonary fibrosis in mice
Takemasa, A., Ishii, Y., & Fukuda, T. (2012) · European Respiratory Journal · doi:10.1183/09031936.00127011 · Cited by 140
Lu, Y., Azad, N., Wang, L., Iyer, A. K. V., Castranova, V., Jiang, B.-H., & Rojanasakul, Y. (2010) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2009-0002oc · Cited by 138
Therapeutic targets in idiopathic pulmonary fibrosis
Kolb, M. R. J., Bonella, F., & Wollin, L. (2017) · Respiratory Medicine · doi:10.1016/j.rmed.2017.07.062 · Cited by 135
Wang, K., Zhang, T., Lei, Y., Li, X., Jiang, J., Lan, J., Liu, Y., Chen, H., Gao, W., Xie, N., et al. (2017) · Autophagy · doi:10.1080/15548627.2017.1409405 · Cited by 135
Pirfenidone attenuates lung fibrotic fibroblast responses to transforming growth factor-β1
Jin, J., Togo, S., Kadoya, K., Tulafu, M., Namba, Y., Iwai, M., Watanabe, J. A., Nagahama, K. Y., Okabe, T., Hidayat, M., et al. (2019) · Respiratory Research · doi:10.1186/s12931-019-1093-z · Cited by 134
Betensley, A. D., Sharif, R., & Karamichos, D. (2016) · Journal of Clinical Medicine · doi:10.3390/jcm6010002 · Cited by 127
Idiopathic Pulmonary Fibrosis: A Disorder of Epithelial Cell Dysfunction
Zoz, D. F., Lawson, W. E., & Blackwell, T. S. (2011) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e31821a9d8e · Cited by 122
Tubastatin ameliorates pulmonary fibrosis by targeting the TGFβ-PI3K-Akt pathway
Saito, S., Zhuang, Y., Shan, B., Danchuk, S. D., Luo, F., Korfei, M., Günther, A., & Lasky, J. A. (2017) · PLoS ONE · doi:10.1371/journal.pone.0186615 · Cited by 119
Moore, C. M., Blumhagen, R. Z., Yang, I. V., Walts, A. D., Powers, J., Walker, T., Bishop, M. M., Russell, P. H., Vestal, B. E., Cardwell, J., et al. (2019) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201810-1891oc · Cited by 119
Yan, W., Wu, Q., Yao, W., Li, Y., Liu, Y., Yuan, J., Han, R., Yang, J., Ji, X., & Ni, C. (2017) · Scientific Reports · doi:10.1038/s41598-017-11904-8 · Cited by 115
Münster, P. N., Aggarwal, R. R., Hong, D. S., Schellens, J. H. M., van der Noll, R., Specht, J. M., Witteveen, P. O., Werner, T. L., Dees, E. C., Bergsland, E. K., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1665 · Cited by 114
Todd, N., Scheraga, Galvin, Iacono, Britt, Luzina, Burke, & Atamas (2013) · Journal of Inflammation Research · doi:10.2147/jir.s40673 · Cited by 113
Matrix regulation of idiopathic pulmonary fibrosis: the role of enzymes
Clarke, D. L., Carruthers, A. M., Mustelin, T., & Murray, L. A. (2013) · Fibrogenesis & Tissue Repair · doi:10.1186/1755-1536-6-20 · Cited by 111
Differential role of regulatory T cells in early and late stages of pulmonary fibrosis
Boveda-Ruiz, D., D’Alessandro-Gabazza, C. N., Toda, M., Takagi, T., Naito, M., Matsushima, Y., Matsumoto, T., Kobayashi, T., Gil-Bernabe, P., Chelakkot-Govindalayathil, A.-L., et al. (2013) · Immunobiology · doi:10.1016/j.imbio.2012.05.020 · Cited by 110
Coagulation Cascade Proteinases in Lung Injury and Fibrosis
Chambers, R. C., & Scotton, C. J. (2012) · Proceedings of the American Thoracic Society · doi:10.1513/pats.201201-006aw · Cited by 105
Arras, M., Huaux, F., Vink, A., Delos, M., Coutelier, J., Many, M., Barbarin, V., Renauld, J., & Lison, D. (2001) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/ajrcmb.24.4.4249 · Cited by 102
Molina‐Molina, M., Machahua, C., Vicens‐Zygmunt, V., Llatjós, R., Escobar, I., Sala, E., Luburich-Hernaiz, P., Dorca, J., & Montes‐Worboys, A. (2018) · BMC Pulmonary Medicine · doi:10.1186/s12890-018-0626-4 · Cited by 102
Apoptosis in lung injury and remodeling
Li, X., Shu, R., Filippatos, G. S., & Uhal, B. D. (2004) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00519.2004 · Cited by 101
Proteinase-activated receptors in fibroproliferative lung disease
José, R. J. P., Williams, A. E., & Chambers, R. C. (2013) · Thorax · doi:10.1136/thoraxjnl-2013-204367 · Cited by 101
Conte, E., Gili, E., Fruciano, M., Korfei, M., Fagone, E., Iemmolo, M., Furno, D. L., Giuffrida, R., Crimi, N., Günther, A., et al. (2013) · Laboratory Investigation · doi:10.1038/labinvest.2013.6 · Cited by 100
Role of Protease-activated Receptor-2 in Idiopathic Pulmonary Fibrosis
Wygrecka, M., Kwapiszewska, G., Jabłońska, E., von Gerlach, S., Henneke, I., Zakrzewicz, D., Günther, A., Preissner, K. T., & Markart, P. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201009-1479oc · Cited by 99
Rapamycin Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
Korfhagen, T. R., Cras, T. D. L., Davidson, C. R., Schmidt, S., Ikegami, M., Whitsett, J. A., & Hardie, W. D. (2009) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2008-0377oc · Cited by 99
O’Dwyer, D. N., Ashley, S. L., & Moore, B. B. (2016) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00221.2016 · Cited by 99
Ding, Q., Gladson, C. L., Wu, H., Hayasaka, H., & Olman, M. A. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m803645200 · Cited by 98
Nintedanib for the treatment of idiopathic pulmonary fibrosis
Varone, F., Sgalla, G., Iovene, B., Bruni, T., & Richeldi, L. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1425681 · Cited by 98
Oxidant/Antioxidant Disequilibrium in Idiopathic Pulmonary Fibrosis Pathogenesis
Cameli, P., Carleo, A., Bergantini, L., Landi, C., Prasse, A., & Bargagli, E. (2019) · Inflammation · doi:10.1007/s10753-019-01059-1 · Cited by 98
Galati, D., De Martino, M., Trotta, A., Rea, G., Bruzzese, D., Cicchitto, G., Stanziola, A. A., Napolitano, M., Sanduzzi, A., & Bocchino, M. (2014) · Cytokine · doi:10.1016/j.cyto.2013.12.003 · Cited by 95
Zhang, X.-L., Xing, R., Chen, L., Liu, C., & Miao, Z. (2016) · Molecular Medicine Reports · doi:10.3892/mmr.2016.5960 · Cited by 95
Liu, M.-W., Su, M.-X., Tang, D.-Y., Hao, L., Xun, X.-H., & Huang, Y.-Q. (2019) · BMC Pulmonary Medicine · doi:10.1186/s12890-019-0799-5 · Cited by 94
AKT2 Regulates Pulmonary Inflammation and Fibrosis via Modulating Macrophage Activation
Nie, Y., Sun, L., Wu, Y., Yang, Y., Wang, J., He, H., Hu, Y., Chang, Y., Liang, Q., Zhu, J., et al. (2017) · The Journal of Immunology · doi:10.4049/jimmunol.1601503 · Cited by 93
Self-citationPharmacologic inhibition of lactate production prevents myofibroblast differentiation
Kottmann, R. M., Trawick, E. C., Judge, J., Wahl, L. A., Epa, A. P., Owens, K. M., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2015) · American Journal of Physiology-Lung Cellular and Molecular Physiology · doi:10.1152/ajplung.00058.2015 · Cited by 91
Kral-Pointner, J. B., Kuttke, M., Schrottmaier, W. C., Birnecker, B., Warszawska, J. M., Wernig, C., Paar, H., Salzmann, M., Sahin, E., Brunner, J. S., et al. (2016) · Scientific Reports · doi:10.1038/srep23034 · Cited by 87
Evolution of PI3Kγ and δ Inhibitors for Inflammatory and Autoimmune Diseases
Perry, M. W. D., Abdulai, R. M., Mogemark, M., Petersen, J. F. W., Thomas, M. J., Valastro, B., & Eriksson, A. W. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b01298 · Cited by 87
Fibrocytes in pulmonary fibrosis: a brief synopsis
Maharaj, S. S., Shimbori, C., & Kolb, M. R. J. (2013) · European Respiratory Review · doi:10.1183/09059180.00007713 · Cited by 84
Phosphoinositide 3‐kinase signalling in lung disease: leucocytes and beyond
Medina‐Tato, D. A., Ward, S. G., & Watson, M. (2007) · Immunology · doi:10.1111/j.1365-2567.2007.02663.x · Cited by 82
Günther, A., MOSAVI, P., Ruppert, C., Heinemann, S., Temmesfeld‐Wollbrück, B., Velcovsky, H. G., Morr, H., Grimminger, F., WALMRATH, D., & Seeger, W. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1613933 · Cited by 79
Epithelial Injury and Dysfunction in the Pathogenesis of Idiopathic PulmonaryFibrosis
Winters, N. I., Burman, A., Kropski, J. A., & Blackwell, T. S. (2019) · The American Journal of the Medical Sciences · doi:10.1016/j.amjms.2019.01.010 · Cited by 78
Idiopathic pulmonary fibrosis and a role for autoimmunity
Hoyne, G. F., Elliott, H., Mutsaers, S. E., & Prêle, C. M. (2017) · Immunology and Cell Biology · doi:10.1038/icb.2017.22 · Cited by 77
Dvorak, H. F. (2019) · Seminars in Thrombosis and Hemostasis · doi:10.1055/s-0039-1687908 · Cited by 77
Leptin promotes pulmonary fibrosis development by inhibiting autophagy via PI3K/Akt/mTOR pathway
Gui, X., Chen, H., Cai, H., Sun, L., & Gu, L. (2018) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2018.03.039 · Cited by 76
γδ T Cells Attenuate Bleomycin-Induced Fibrosis through the Production of CXCL10
Pociask, D. A., Chen, K., Choi, S. M., Oury, T. D., Steele, C. H., & Kolls, J. K. (2011) · American Journal Of Pathology · doi:10.1016/j.ajpath.2010.11.055 · Cited by 75
Chen, Y., Li, C., Weng, D., Song, L., Tang, W., Dai, W., Yu, Y., Liu, F., Zhao, M., Lu, C., et al. (2014) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.11.012 · Cited by 75
Exposures and Idiopathic Lung Disease
Taskar, V. S., & Coultas, D. (2008) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0028-1101277 · Cited by 70
Lee, K.-I., Su, C., Fang, K., Wu, C.-C., Wu, C., & Chen, Y. (2020) · Scientific Reports · doi:10.1038/s41598-020-66644-z · Cited by 70
Coagulation and anticoagulation in idiopathic pulmonary fibrosis
Crooks, M. G., & Hart, S. P. (2015) · European Respiratory Review · doi:10.1183/16000617.00008414 · Cited by 68
Nitric Oxide Mediates Bleomycin‐induced Angiogenesis and Pulmonary Fibrosis via Regulation of VEGF
Iyer, A. K. V., Ramesh, V., Castro, C. A., Kaushik, V., Kulkarni, Y. M., Wright, C. A., Venkatadri, R., Rojanasakul, Y., & Azad, N. (2015) · Journal of Cellular Biochemistry · doi:10.1002/jcb.25192 · Cited by 67
Spassov, S. G., Donus, R., Ihle, P. M., Engelstaedter, H., Hoetzel, A., & Faller, S. (2017) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2017/3715037 · Cited by 67
Lin, C., Borensztajn, K., & Spek, C. A. (2017) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.13623 · Cited by 66
Hyperoside Attenuates Bleomycin-Induced Pulmonary Fibrosis Development in Mice
Huang, J., Tong, X., Zhang, L., Zhang, Y., Wang, L., Wang, D., Zhang, S., & Fan, H. S. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.550955 · Cited by 66
Inhibition of PI3K by PX-866 Prevents Transforming Growth Factor-α–Induced Pulmonary Fibrosis
Cras, T. D. L., Korfhagen, T. R., Davidson, C. R., Schmidt, S., Fenchel, M. C., Ikegami, M., Whitsett, J. A., & Hardie, W. D. (2009) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090123 · Cited by 63
The dietary antioxidant quercetin reduces hallmarks of bleomycin-induced lung fibrogenesis in mice
Boots, A. W., Veith, C., Albrecht, C., Bartholomé, R., Drittij-Reijnders, M.-J., Claessen, S. M. H., Bast, A., Rosenbruch, M., Jonkers, L., van Schooten, F., et al. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1142-x · Cited by 63
Bellaye, P., & Kolb, M. R. J. (2015) · BMC Medicine · doi:10.1186/s12916-015-0412-6 · Cited by 61
Qiu, T., Tian, Y., Gao, Y., Ma, M., Li, H., Liu, X., Wu, H., Zhang, Y., Ding, H. J., Cao, M., et al. (2019) · Aging · doi:10.18632/aging.102262 · Cited by 61
Profibrotic Effect of IL-9 Overexpression in a Model of Airway Remodeling
van den Brûle, S., Heymans, J., Havaux, X., Renauld, J., Lison, D., Huaux, F., & Denis, O. (2007) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0397oc · Cited by 60
Malli, F., Koutsokera, A., Paraskeva, E., Zakynthinos, E. G., Papagianni, M., Makris, D., Tsilioni, I., Molyvdas, P. A., Gourgoulianis, K. I., & Daniil, Z. D. (2013) · PLoS ONE · doi:10.1371/journal.pone.0053658 · Cited by 59
Liu, T., Santos, F. G. D. L., Zhao, Y., Wu, Z. B., Rinke, A. E., Kim, K. K., & Phan, S. H. (2019) · Journal of Biological Chemistry · doi:10.1074/jbc.ra118.006615 · Cited by 59
Cyr61 and CTGF are molecular markers of bladder wall remodeling after outlet obstruction
Chaqour, B., Whitbeck, C., Han, J., Macarak, E. J., Horan, P., Chichester, P., & Levin, R. M. (2002) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00131.2002 · Cited by 58
Extracellular matrix microenvironment contributes actively to pulmonary fibrosis
Shimbori, C., Gauldie, J., & Kolb, M. R. J. (2013) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0b013e328363f4de · Cited by 54
Pharmacologic targeting of the ATX/LPA axis attenuates bleomycin-induced pulmonary fibrosis
Ninou, I., Kaffe, E., Müller, S., Budd, D. C., Stevenson, C. S., Ullmer, C., & Aidinis, V. (2018) · Pulmonary Pharmacology & Therapeutics · doi:10.1016/j.pupt.2018.08.003 · Cited by 53
Levy, B. P., Spira, A. I., Becker, D. J., Evans, T. L., Schnadig, I. D., Camidge, D. R., Bauman, J. E., Hausman, D. F., Walker, L. N., Nemunaitis, J. J., et al. (2014) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000183 · Cited by 52
Influence of early neutrophil depletion on MMPs/TIMP-1 balance in bleomycin-induced lung fibrosis
Manoury, B., Nénan, S., Guénon, I., Lagente, V., & Boichot, E. (2007) · International Immunopharmacology · doi:10.1016/j.intimp.2007.02.009 · Cited by 50
Zou, L., Chen, S., Li, L., & Wu, T. (2017) · Experimental and Toxicologic Pathology · doi:10.1016/j.etp.2017.04.001 · Cited by 50
Sun, Y., Zhang, Y., & Chi, P. (2018) · Molecular Medicine Reports · doi:10.3892/mmr.2018.9423 · Cited by 50
Hyperoside attenuates OVA-induced allergic airway inflammation by activating Nrf2
Ye, P., Yang, X., Chen, X., & Shi, C. (2017) · International Immunopharmacology · doi:10.1016/j.intimp.2017.01.003 · Cited by 49
Selectins and chemokines use shared and distinct signals to activate β2 integrins in neutrophils
Yago, T., Zhang, N., Zhao, L., Abrams, C. S., & McEver, R. P. (2018) · Blood Advances · doi:10.1182/bloodadvances.2017015602 · Cited by 49
Lin, G., Gai, R., Chen, Z., Wang, Y., Liao, S., Dong, R., Zhu, H., Gu, Y., He, Q., & Yang, B. (2014) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2014.02.011 · Cited by 48
Self-citationLin, S., Jin, J., Liu, Y., Tian, H., Zhang, Y., Fu, R., Zhang, J., Wang, M., Du, T., Ji, M., et al. (2019) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.9b00969 · Cited by 47
Role of Microbial Agents in Pulmonary Fibrosis .
Chioma, O. S., & Drake, W. P. (2017) · PubMed Central · Cited by 46
Zhang, L., Li, Y., Liang, C., & Yang, W. (2013) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2013.1565 · Cited by 44
Akt1 regulates pulmonary fibrosis via modulating IL-13 expression in macrophages
Nie, Y., Hu, Y., Yu, K., Zhang, D., Shi, Y., Li, Y., Sun, L., & Qian, F. (2019) · Innate Immunity · doi:10.1177/1753425919861774 · Cited by 42
Nintedanib for Idiopathic Pulmonary Fibrosis
Tepede, A. K., & Yogaratnam, D. (2017) · Journal of Pharmacy Practice · doi:10.1177/0897190017735242 · Cited by 40
PIK3CAH1047R Accelerates and Enhances KRASG12D-Driven Lung Tumorigenesis
Green, S., Trejo, C. L., & McMahon, M. (2015) · Cancer Research · doi:10.1158/0008-5472.can-15-1249 · Cited by 38
Zolak, J. S., & de Andrade, J. A. (2012) · Immunology and Allergy Clinics of North America · doi:10.1016/j.iac.2012.08.006 · Cited by 38
Sapru, A., Wiemels, J. L., Witte, J. S., Ware, L. B., & Matthay, M. A. (2006) · Intensive Care Medicine · doi:10.1007/s00134-006-0223-5 · Cited by 37
Pathognomonic remodeling of blood and lymphatic capillaries in idiopathic pulmonary fibrosis
Ebina, M. (2016) · Respiratory Investigation · doi:10.1016/j.resinv.2016.08.005 · Cited by 35
IL-9 Protects against Bleomycin-Induced Lung Injury
Arras, M., Louahed, J., Heilier, J.-F., Delos, M., Brombacher, F., Renauld, J., Lison, D., & Huaux, F. (2005) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)62236-5 · Cited by 27
Rapamycin increases CCN2 expression of lung fibroblasts via phosphoinositide 3-kinase
Xu, X., Dai, H., Geng, J., Wan, X., Huang, X., Li, F., Jiang, D., & Wang, C. (2015) · Laboratory Investigation · doi:10.1038/labinvest.2015.68 · Cited by 26
GOLGA2 loss causes fibrosis with autophagy in the mouse lung and liver
Park, S. J., Kim, S., Kim, M. J., Hong, Y., Lee, A. Y., Lee, H., Tran, Q., Kim, M., Cho, H., Park, J., et al. (2017) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2017.11.049 · Cited by 26
Nho, R. S., & Polunovsky, V. A. (2013) · Translation · doi:10.4161/trla.23934 · Cited by 13
Wu, X., Li, W., Luo, Z., et al. (2020) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2020/2416132 · Cited by 10
PI3-Kinase δγ Catalytic Isoforms Regulate the Th-17 Response in Tuberculosis
Leisching, G. R. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02583 · Cited by 4
Idiopathic Pulmonary Fibrosis: Clinical Behavior, Pathogenic Mechanisms and Therapeutic Approach
Selman, M., & Pardo, A. (2015) · Barcelona Respiratory Network · doi:10.23866/brnrev:2015-m0003 · Cited by 1
Cited by
Guo, H., Sun, J., Zhang, S., Nie, Y., Zhou, S., & Zeng, Y. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1205948 · Cited by 41
Zheng, Y., Schupp, J., Adams, T., Clair, G., Justet, A., Ahangari, F., Yan, X., Hansen, P., Carlon, M., Cortesi, E., et al. (2023) · doi:10.21203/rs.3.rs-3676579/v1 · Cited by 34
Metadata
- Authors
- Wang, J., Hu, K., Cai, X., Yang, B., He, Q., Wang, J., & Weng, Q.
- Venue
- Acta Pharmaceutica Sinica B
- Publisher
- Elsevier BV
- Published
- 2022-01
- Volume
- 12
- Issue
- 1
- Pages
- 18-32
- ISSN
- 2211-3835 (ISSN-L)
- OpenAlex
- W3192380806
- Cited by
- 450
- References
- 188
- FWCI
- 30.35
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.